CN108635571A - Irisin（irisin）Application in preventing and treating Severe Acute Pancreatitis SAP drug - Google Patents
Irisin（irisin）Application in preventing and treating Severe Acute Pancreatitis SAP drug Download PDFInfo
- Publication number
- CN108635571A CN108635571A CN201810797454.4A CN201810797454A CN108635571A CN 108635571 A CN108635571 A CN 108635571A CN 201810797454 A CN201810797454 A CN 201810797454A CN 108635571 A CN108635571 A CN 108635571A
- Authority
- CN
- China
- Prior art keywords
- irisin
- acute pancreatitis
- severe acute
- pancreatitis sap
- sap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to field of medicaments, specifically disclose application of the irisin (irisin) in preventing and treating Severe Acute Pancreatitis SAP drug, in mouse Severe Acute Pancreatitis SAP, pancreas function can be significantly improved by being injected intravenously exogenous irisin, mitigate pancreatic cell er stress, pancreatic tissue damage and cell death are reduced, shows that irisin can significantly improve Severe Acute Pancreatitis SAP；Irisin is applied to drug development; it is injected intravenously when acute pancreatitis is made a definite diagnosis in emergency treatment; when blocking and preventing pancreatitis; local inflammation reaction progresses to systemic inflammatory response syndrome or mitigates the widened effect of systemic inflammatory response syndrome chain type; to inhibit pancreatitis worsening, plays the local internal organs of protection and prevent the generation of multiple organ failure syndrome；The present invention provides completely new selection and thinking to prevent at present and treating Severe Acute Pancreatitis SAP.
Description
Technical field
The present invention relates to field of medicaments, and in particular to irisin (irisin) is preventing and treating Severe Acute Pancreatitis SAP medicine
Application in object.
Background technology
Acute pancreatitis (Acute Pancreatitis, AP) is clinical common acute abdomen, the wherein disease of 20%-25%
People's clinically state of an illness weight, may occur in which locally or systemically complication, multiple organ failure or even threat to life occurs, referred to as heavy
Disease acute pancreatitis (Severe Acute Pancreatitis, SAP).The SAP causes of disease are complicated, and pathogenesis is not yet completely clear,
Estimate according to the World Health Organization, will become the No.1 cause of death of pancreatic disease to the year two thousand twenty SAP.By nearly research in 30 years, I
The therapeutic effect of state's Severe Acute Pancreatitis SAP has had significant raising, treatment viewpoint also to reach common recognition in principle, that
Just be to discriminate between different pathogeny, different stadium individualized treatment scheme.The therapeutic effect of acute pancreatitis at present, overall survival
Up to 83%, the wherein survival rate of operative treatment is up to 70% or more, and non-operative treatment person is up to 90% or so.Compared with the past, this
One curative effect is gratifying, but can't be satisfactory, because also 20%~30% patient cannot cure, and the course for the treatment of is long,
Costly, patient's pain is big.Affect the treatment it is most important the reason is that, also lacked early stage the course of disease really can blocking condition development
Specific treatment；Operation treatment still has the very high death rate, simple to be difficult to improve by operation or non-operative treatment
Its survival rate；In the different phase of the course of disease, the selection of surgical indication and the grasp of opportunity of operation, or even in operation method, drainage
Technical aspect usually there is also the difference in understanding, makes opportunity of operation be delayed, Residue；To severe complication such as fungi deep
Infection and pancreatic encephalopathy understanding are insufficient, and the death rate and disability rate are still very high.
The prevention of Severe Acute Pancreatitis SAP is mainly positive operative drainage at present, gives effective life supportive treatment, suppression
Systemic inflammatorome waterfall type chain reaction progress processed aggravates.
Irisin is a kind of muscle factor for being found in 2012, current study show that irisin can promote the white of mouse
Adipocyte occurs brown cell sample and changes, and plays a significant role in energetic supersession and diabetes B.Irisin is type III
Fibronectin component includes albumen 5 (fibronectin type IIIdomain-containing protein 5, FNDC5)
What is formed after proteolysis can secrete polypeptide segment.Currently, any report that there is no irisin to be applied in Severe Acute Pancreatitis SAP
Road.
Invention content
The purpose of the present invention is to provide irisins (irisin) in preventing and treating Severe Acute Pancreatitis SAP drug
Using.
To achieve the goals above, the present invention provides following technical scheme：
The present invention provides application of the irisin (irisin) in preventing and treating Severe Acute Pancreatitis SAP drug.
The Severe Acute Pancreatitis SAP refers to the Severe Acute Pancreatitis SAP mouse model of L-arginine induction.
It is abnormal that the irisin can alleviate pancreas function caused by Severe Acute Pancreatitis SAP.
The irisin can mitigate pancreatic tissue Damage Induced by Reactive Oxygen Species caused by Severe Acute Pancreatitis SAP.
The irisin can mitigate pancreatic cell injury of mitochondria caused by Severe Acute Pancreatitis SAP.
The irisin can mitigate pancreatic cell er stress caused by Severe Acute Pancreatitis SAP.
The present invention effective income be：Irisin is applied to drug development, the vein when acute pancreatitis is made a definite diagnosis in emergency treatment
Injection blocks and prevents when pancreatitis that local inflammation reaction progresses to systemic inflammatory response syndrome or to mitigate systemic inflammatorome anti-
The widened effect of syndrome chain type is answered, to inhibit pancreatitis worsening, the local internal organs of protection is played and prevents multiple organ dysfunction
The generation of wasting syndrome.The present invention provides completely new selection and thinking for current preventing/treating Severe Acute Pancreatitis SAP.
Description of the drawings
Fig. 1：It is abnormal that pancreas function caused by Severe Acute Pancreatitis SAP is alleviated in irisin intraperitoneal injection.
Fig. 2：Irisin intraperitoneal injection mitigates pancreatic tissue caused by Severe Acute Pancreatitis SAP and damages.
Fig. 3：Irisin intraperitoneal injection mitigates pancreatic cell injury of mitochondria caused by Severe Acute Pancreatitis SAP.
Fig. 4：Irisin intraperitoneal injection mitigates pancreatic cell er stress caused by Severe Acute Pancreatitis SAP.
Fig. 5：The molecular structure of irisin.
Specific implementation mode
It is further illustrated the present invention below in conjunction with Figure of description and specific embodiment, but embodiment is not to the present invention
It limits in any form.Irisin used is synthesized by biotech firm, can directly buy commercially available product.Unless stated otherwise, originally
The reagent used, method and apparatus are invented as the art conventional reagent, method and apparatus.
Embodiment 1：By 100 microgram irisins, 10 milliliters of physiological saline solutions, it is configured to 10ug/ml injections.
Effect of the irisin to Severe Acute Pancreatitis SAP is studied by taking this injection as an example.
Zoopery.
One, experimental animals：20-25g male C 57 BL/6 J mouses are taken to be randomly divided into 4 groups, every group 6：
Normal group (Sham)；
Severe Acute Pancreatitis SAP control group：Mouse peritoneal injects 8%L- arginine 4g/kg (Vehicle)；
Severe Acute Pancreatitis SAP high dose irisin treatment group：Mouse peritoneal injects 8%L- arginine 4g/kg, after 2 hours
Give 250 μ g/kg irisins (H-Irisin).
Severe Acute Pancreatitis SAP low dosage irisin treatment group：Mouse peritoneal injects 8%L- arginine 4g/kg, after 2 hours
Give 50ug/kg irisins (L-Irisin).
Two：Model of Severe Acute Pancreatitis makes：Vehicle mouse make severe through 8%L- arginine 4g/kg is injected intraperitoneally
Acute pancreatitis SAP models.Sham groups are through being injected intraperitoneally equal volume physiological saline；H-Irisin groups mouse is through intraperitoneal injection
Give within 2 hours after 8%L- arginine 4g/kg 250 μ g/kg Irisin.L-Irisin group mouse peritoneals inject 8%L- arginine
4g/kg gives 50ug/kg irisins after 2 hours.
Anesthesia takes blood specimen to above-mentioned each mouse under isoflurane after irisin is injected for 24 hours, detects serum pancreatitis index；It is small
Pancreatic tissue is taken after mouse euthanasia, part pancreas is taken to fix row H＆E dyeing with 4% paraformaldehyde；Remaining fresh pancreatic tissue -80
Degree refrigeration, to detect the indexs such as pancreas oxidative stress index and injury of mitochondria.
Three：Experimental result；
1. irisin improves situation to pancreas function after mouse Severe Acute Pancreatitis SAP.Each group mouse blood is detected with kit
Amylase, lipase content in clear sample.The result is shown in Figure 1, Sham is the blank group that do not intervene in figure；Vihicle is severe
Acute pancreatitis control group；H-Irisin is Severe Acute Pancreatitis SAP high dose Irisin treatment groups；L-Irisin is that severe is anxious
Property pancreatitis low dosage Irisin treatment groups.* is indicated in figure and Sham groups are more variant；# is indicated and Vihicle groups have difference
It is different；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly improve pancreas function situation after mouse Severe Acute Pancreatitis SAP.
2. irisin is to pancreatic tissue degree of impairment after mouse Severe Acute Pancreatitis SAP.As a result see Fig. 2, fixed pancreas group
It knits and is embedded and be sliced with paraffin wax block, with haematoxylin eosin stains (H＆E).Using histological score and downright bad face is measured to result
Product.Organize methods of marking：Including following 6 indexs：Cytoplasm colour fading, vacuolation, karyopycnosis, karyorrhexis, core are subsided and red thin
Born of the same parents are retarded by silt, and each index is divided into 1 (light), 2 (in), 3 (weight)s, obatained score is that 6 mouse that must be divided into of above 6 indexs are put down
Mean value.Necrosis area is estimated by H＆E outcome measurements.* is indicated in figure and Sham groups are more variant；# is indicated and Vihicle groups
It is variant；※ is indicated and H-irisin groups are variant.
The result shows that：Pancreatic tissue is damaged after tail element can significantly mitigate mouse Severe Acute Pancreatitis SAP.
3. irisin improves situation to pancreatic tissue injury of mitochondria after mouse Severe Acute Pancreatitis SAP.Use Western-
Blot technologies detect the indexs such as PGC-1 α, DRP-1, ATPB and PINK in each group mice pancreatic tissue.As a result Fig. 3 is seen, in figure
Sham is the blank group that do not intervene；Vihicle is Severe Acute Pancreatitis SAP control group；H-Irisin is Severe Acute Pancreatitis SAP
High dose Irisin treatment groups；L-Irisin is Severe Acute Pancreatitis SAP low dosage Irisin treatment groups.* expressions and Sham in figure
Group is more variant；# is indicated and Vihicle groups are variant；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly mitigate pancreatic cell injury of mitochondria after mouse Severe Acute Pancreatitis SAP.
Therefore, the present invention may be used as the preparation of preventing/treating Severe Acute Pancreatitis SAP drug.
4. irisin improves situation to pancreatic cell er stress after mouse Severe Acute Pancreatitis SAP.Use Western-
Blot technologies detect the indexs such as IRE1- α and GRP78 in each group mice pancreatic tissue.As a result see Fig. 4, Sham is not have in figure
The blank group of intervention；Vihicle is Severe Acute Pancreatitis SAP control group；H-Irisin is Severe Acute Pancreatitis SAP high dose
Irisin treatment groups；L-Irisin is Severe Acute Pancreatitis SAP low dosage Irisin treatment groups.* is indicated in figure and Sham groups compare
It is variant；# is indicated and Vihicle groups are variant；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly mitigate pancreatic cell er stress feelings after mouse Severe Acute Pancreatitis SAP
Condition.
Data are all made of means standard deviation.Statistical method is examined using SNK, P<0.05 has significant difference.
Embodiment：By 100 microgram irisins, 5 milliliters of physiological saline solutions, it is configured to 20ug/ml injections.
Effect of the irisin to Severe Acute Pancreatitis SAP is studied by taking this injection as an example.
Zoopery.
One, experimental animals：20-25g male C 57 BL/6 J mouses are taken to be randomly divided into 4 groups, every group 6：
Normal group (Sham)；
Severe Acute Pancreatitis SAP control group：Mouse peritoneal injects 8%L- arginine 4g/kg (Vehicle)；
Severe Acute Pancreatitis SAP high dose irisin treatment group：Mouse peritoneal injects 8%L- arginine 4g/kg, after 2 hours
Give 250 μ g/kg irisins (H-Irisin).
Severe Acute Pancreatitis SAP low dosage irisin treatment group：Mouse peritoneal injects 8%L- arginine 4g/kg, after 2 hours
Give 50ug/kg irisins (L-Irisin).
Two：Model of Severe Acute Pancreatitis makes：Vehicle mouse make severe through 8%L- arginine 4g/kg is injected intraperitoneally
Acute pancreatitis SAP models.Sham groups are through being injected intraperitoneally equal volume physiological saline；H-Irisin groups mouse is through intraperitoneal injection
Give within 2 hours after 8%L- arginine 4g/kg 250 μ g/kg Irisin.L-Irisin group mouse peritoneals inject 8%L- arginine
4g/kg gives 50ug/kg irisins after 2 hours.
Anesthesia takes blood specimen to above-mentioned each mouse under isoflurane after irisin is injected for 24 hours, detects serum pancreatitis index；It is small
Pancreatic tissue is taken after mouse euthanasia, part pancreas is taken to fix row H＆E dyeing with 4% paraformaldehyde；Remaining fresh pancreatic tissue -80
Degree refrigeration, to detect the indexs such as pancreas oxidative stress index and injury of mitochondria.
Three：Experimental result；
1. irisin improves situation to pancreas function after mouse Severe Acute Pancreatitis SAP.Each group mouse blood is detected with kit
Amylase, lipase content in clear sample.The result is shown in Figure 1, Sham is the blank group that do not intervene in figure；Vihicle is severe
Acute pancreatitis control group；H-Irisin is Severe Acute Pancreatitis SAP high dose Irisin treatment groups；L-Irisin is that severe is anxious
Property pancreatitis low dosage Irisin treatment groups.* is indicated in figure and Sham groups are more variant；# is indicated and Vihicle groups have difference
It is different；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly improve pancreas function situation after mouse Severe Acute Pancreatitis SAP.
2. irisin is to pancreatic tissue degree of impairment after mouse Severe Acute Pancreatitis SAP.As a result see Fig. 2, fixed pancreas group
It knits and is embedded and be sliced with paraffin wax block, with haematoxylin eosin stains (H＆E).Using histological score and downright bad face is measured to result
Product.Organize methods of marking：Including following 6 indexs：Cytoplasm colour fading, vacuolation, karyopycnosis, karyorrhexis, core are subsided and red thin
Born of the same parents are retarded by silt, and each index is divided into 1 (light), 2 (in), 3 (weight)s, obatained score is that 6 mouse that must be divided into of above 6 indexs are put down
Mean value.Necrosis area is estimated by H＆E outcome measurements.* is indicated in figure and Sham groups are more variant；# is indicated and Vihicle groups
It is variant；※ is indicated and H-irisin groups are variant.
The result shows that：Pancreatic tissue is damaged after tail element can significantly mitigate mouse Severe Acute Pancreatitis SAP.
3. irisin improves situation to pancreatic tissue injury of mitochondria after mouse Severe Acute Pancreatitis SAP.Use Western-
Blot technologies detect the indexs such as PGC-1 α, DRP-1, ATPB and PINK in each group mice pancreatic tissue.As a result Fig. 3 is seen, in figure
Sham is the blank group that do not intervene；Vihicle is Severe Acute Pancreatitis SAP control group；H-Irisin is Severe Acute Pancreatitis SAP
High dose Irisin treatment groups；L-Irisin is Severe Acute Pancreatitis SAP low dosage Irisin treatment groups.* expressions and Sham in figure
Group is more variant；# is indicated and Vihicle groups are variant；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly mitigate pancreatic cell injury of mitochondria after mouse Severe Acute Pancreatitis SAP.
Therefore, the present invention may be used as the preparation of preventing/treating Severe Acute Pancreatitis SAP drug.
4. irisin improves situation to pancreatic cell er stress after mouse Severe Acute Pancreatitis SAP.Use Western-
Blot technologies detect the indexs such as IRE1- α and GRP78 in each group mice pancreatic tissue.As a result see Fig. 4, Sham is not have in figure
The blank group of intervention；Vihicle is Severe Acute Pancreatitis SAP control group；H-Irisin is Severe Acute Pancreatitis SAP high dose
Irisin treatment groups；L-Irisin is Severe Acute Pancreatitis SAP low dosage Irisin treatment groups.* is indicated in figure and Sham groups compare
It is variant；# is indicated and Vihicle groups are variant；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly mitigate pancreatic cell er stress feelings after mouse Severe Acute Pancreatitis SAP
Condition.
Data are all made of means standard deviation.Statistical method is examined using SNK, P<0.05 has significant difference.
Embodiment 1：By 100 microgram irisins, 10 milliliters of physiological saline solutions, it is configured to 10ug/ml injections.
Effect of the irisin to Severe Acute Pancreatitis SAP is studied by taking this injection as an example.
Zoopery.
One, experimental animals：20-25g male C 57 BL/6 J mouses are taken to be randomly divided into 4 groups, every group 6：
Normal group (Sham)；
Severe Acute Pancreatitis SAP control group：Mouse peritoneal injects 8%L- arginine 4g/kg (Vehicle)；
Severe Acute Pancreatitis SAP high dose irisin treatment group：Mouse peritoneal injects 8%L- arginine 4g/kg, after 2 hours
Give 250 μ g/kg irisins (H-Irisin).
Severe Acute Pancreatitis SAP low dosage irisin treatment group：Mouse peritoneal injects 8%L- arginine 4g/kg, after 2 hours
Give 50ug/kg irisins (L-Irisin).
Two：Model of Severe Acute Pancreatitis makes：Vehicle mouse make severe through 8%L- arginine 4g/kg is injected intraperitoneally
Acute pancreatitis SAP models.Sham groups are through being injected intraperitoneally equal volume physiological saline；H-Irisin groups mouse is through intraperitoneal injection
Give within 2 hours after 8%L- arginine 4g/kg 250 μ g/kg Irisin.L-Irisin group mouse peritoneals inject 8%L- arginine
4g/kg gives 50ug/kg irisins after 2 hours.
Anesthesia takes blood specimen to above-mentioned each mouse under isoflurane after irisin is injected for 24 hours, detects serum pancreatitis index；It is small
Pancreatic tissue is taken after mouse euthanasia, part pancreas is taken to fix row H＆E dyeing with 4% paraformaldehyde；Remaining fresh pancreatic tissue -80
Degree refrigeration, to detect the indexs such as pancreas oxidative stress index and injury of mitochondria.
Three：Experimental result；
1. irisin improves situation to pancreas function after mouse Severe Acute Pancreatitis SAP.Each group mouse blood is detected with kit
Amylase, lipase content in clear sample.The result is shown in Figure 1, Sham is the blank group that do not intervene in figure；Vihicle is severe
Acute pancreatitis control group；H-Irisin is Severe Acute Pancreatitis SAP high dose Irisin treatment groups；L-Irisin is that severe is anxious
Property pancreatitis low dosage Irisin treatment groups.* is indicated in figure and Sham groups are more variant；# is indicated and Vihicle groups have difference
It is different；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly improve pancreas function situation after mouse Severe Acute Pancreatitis SAP.
2. irisin is to pancreatic tissue degree of impairment after mouse Severe Acute Pancreatitis SAP.As a result see Fig. 2, fixed pancreas group
It knits and is embedded and be sliced with paraffin wax block, with haematoxylin eosin stains (H＆E).Using histological score and downright bad face is measured to result
Product.Organize methods of marking：Including following 6 indexs：Cytoplasm colour fading, vacuolation, karyopycnosis, karyorrhexis, core are subsided and red thin
Born of the same parents are retarded by silt, and each index is divided into 1 (light), 2 (in), 3 (weight)s, obatained score is that 6 mouse that must be divided into of above 6 indexs are put down
Mean value.Necrosis area is estimated by H＆E outcome measurements.* is indicated in figure and Sham groups are more variant；# is indicated and Vihicle groups
It is variant；※ is indicated and H-irisin groups are variant.
The result shows that：Pancreatic tissue is damaged after tail element can significantly mitigate mouse Severe Acute Pancreatitis SAP.
3. irisin improves situation to pancreatic tissue injury of mitochondria after mouse Severe Acute Pancreatitis SAP.Use Western-
Blot technologies detect the indexs such as PGC-1 α, DRP-1, ATPB and PINK in each group mice pancreatic tissue.As a result Fig. 3 is seen, in figure
Sham is the blank group that do not intervene；Vihicle is Severe Acute Pancreatitis SAP control group；H-Irisin is Severe Acute Pancreatitis SAP
High dose Irisin treatment groups；L-Irisin is Severe Acute Pancreatitis SAP low dosage Irisin treatment groups.* expressions and Sham in figure
Group is more variant；# is indicated and Vihicle groups are variant；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly mitigate pancreatic cell injury of mitochondria after mouse Severe Acute Pancreatitis SAP.
Therefore, the present invention may be used as the preparation of preventing/treating Severe Acute Pancreatitis SAP drug.
4. irisin improves situation to pancreatic cell er stress after mouse Severe Acute Pancreatitis SAP.Use Western-
Blot technologies detect the indexs such as IRE1- α and GRP78 in each group mice pancreatic tissue.As a result see Fig. 4, Sham is not have in figure
The blank group of intervention；Vihicle is Severe Acute Pancreatitis SAP control group；H-Irisin is Severe Acute Pancreatitis SAP high dose
Irisin treatment groups；L-Irisin is Severe Acute Pancreatitis SAP low dosage Irisin treatment groups.* is indicated in figure and Sham groups compare
It is variant；# is indicated and Vihicle groups are variant；※ is indicated and H-irisin groups are variant.
The result shows that：Irisin can significantly mitigate pancreatic cell er stress feelings after mouse Severe Acute Pancreatitis SAP
Condition.
Data are all made of means standard deviation.Statistical method is examined using SNK, P<0.05 has significant difference.
Claims (6)
1. application of the irisin (irisin) in preventing and treating Severe Acute Pancreatitis SAP drug.
2. application according to claim 1, which is characterized in that the Severe Acute Pancreatitis SAP refers to L-arginine induction
Severe Acute Pancreatitis SAP mouse model.
3. application according to claim 1, which is characterized in that the irisin can alleviate Severe Acute Pancreatitis SAP and draw
The pancreas function risen is abnormal.
4. application according to claim 1, which is characterized in that the irisin can mitigate Severe Acute Pancreatitis SAP and draw
The pancreatic tissue Damage Induced by Reactive Oxygen Species risen.
5. application according to claim 1, which is characterized in that the irisin can mitigate Severe Acute Pancreatitis SAP and draw
The pancreatic cell injury of mitochondria risen.
6. application according to claim 1, which is characterized in that the irisin can mitigate Severe Acute Pancreatitis SAP and draw
The pancreatic cell er stress risen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810797454.4A CN108635571B (en) | 2018-07-19 | 2018-07-19 | Application of irisin in preparation of medicine for preventing and treating severe acute pancreatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810797454.4A CN108635571B (en) | 2018-07-19 | 2018-07-19 | Application of irisin in preparation of medicine for preventing and treating severe acute pancreatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108635571A true CN108635571A (en) | 2018-10-12 |
| CN108635571B CN108635571B (en) | 2021-10-22 |
Family
ID=63759818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810797454.4A Active CN108635571B (en) | 2018-07-19 | 2018-07-19 | Application of irisin in preparation of medicine for preventing and treating severe acute pancreatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108635571B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113267636A (en) * | 2021-06-07 | 2021-08-17 | 苏州大学附属第一医院 | Application of P2Y12 receptor and antagonist thereof in diagnosis and treatment of acute pancreatitis |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573857A (en) * | 2009-10-09 | 2012-07-11 | 雀巢产品技术援助有限公司 | Methods for preventing or treating sarcopenia and muscle atrophy in animals |
| CN103585620A (en) * | 2013-11-16 | 2014-02-19 | 中国人民解放军第三军医大学第三附属医院 | Application of irisin to preparation of drugs for preventing myocardial ischemia-reperfusion injury |
| CN104623640A (en) * | 2015-01-29 | 2015-05-20 | 南京医科大学 | Application of irisin in preparation of antihyperglycemic medicines |
| CN104673802A (en) * | 2015-03-12 | 2015-06-03 | 山东大学第二医院 | Irisin protein encoded nucleic acid molecule and method utilizing nucleic acid molecule to efficiently express irisin protein |
| WO2016081603A1 (en) * | 2014-11-20 | 2016-05-26 | Stc.Unm | Irisin-related cancer treatments |
| WO2017081556A1 (en) * | 2015-11-10 | 2017-05-18 | Universita' Degli Studi Di Bari | Pharmacological use of a myokine able to preserve the function and mass of the pancreatic cells under dysmetabolic conditions |
| CN107496908A (en) * | 2017-09-04 | 2017-12-22 | 南京医科大学 | Application of the irisin in anti-inflammatory drug is prepared |
| CN108290937A (en) * | 2015-10-28 | 2018-07-17 | 株式会社柳韩洋行 | Long-acting FGF21 fusion proteins and the pharmaceutical composition comprising it |
-
2018
- 2018-07-19 CN CN201810797454.4A patent/CN108635571B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573857A (en) * | 2009-10-09 | 2012-07-11 | 雀巢产品技术援助有限公司 | Methods for preventing or treating sarcopenia and muscle atrophy in animals |
| CN103585620A (en) * | 2013-11-16 | 2014-02-19 | 中国人民解放军第三军医大学第三附属医院 | Application of irisin to preparation of drugs for preventing myocardial ischemia-reperfusion injury |
| WO2016081603A1 (en) * | 2014-11-20 | 2016-05-26 | Stc.Unm | Irisin-related cancer treatments |
| CN104623640A (en) * | 2015-01-29 | 2015-05-20 | 南京医科大学 | Application of irisin in preparation of antihyperglycemic medicines |
| CN104673802A (en) * | 2015-03-12 | 2015-06-03 | 山东大学第二医院 | Irisin protein encoded nucleic acid molecule and method utilizing nucleic acid molecule to efficiently express irisin protein |
| CN108290937A (en) * | 2015-10-28 | 2018-07-17 | 株式会社柳韩洋行 | Long-acting FGF21 fusion proteins and the pharmaceutical composition comprising it |
| WO2017081556A1 (en) * | 2015-11-10 | 2017-05-18 | Universita' Degli Studi Di Bari | Pharmacological use of a myokine able to preserve the function and mass of the pancreatic cells under dysmetabolic conditions |
| CN107496908A (en) * | 2017-09-04 | 2017-12-22 | 南京医科大学 | Application of the irisin in anti-inflammatory drug is prepared |
Non-Patent Citations (6)
| Title |
|---|
| CHEN SHAYAN等: "Characterization of serum irisin in patients with severe acute pancreatitis", 《EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY》 * |
| REN YIFAN等: "Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis", 《BIOMEDICINE & PHARMACOTHERAPY》 * |
| REN YIFAN等: "Irisin attenuates intestinal injury, oxidative and endoplasmic reticulum stress in mice with L-arginine-induced acute pancreatitis", 《WORLD JOURNAL OF GASTROENTEROLOGY》 * |
| REN YIFAN等: "Low Serum Irisin Concentration Is Associated with Poor Outcomes in Patients with Acute Pancreatitis, and Irisin Administration Protects Against Experimental Acute Pancreatitis", 《ANTIOXIDANTS & REDOX SIGNALING》 * |
| 周顺昌，等: "鸢尾素在胰腺疾病中的相关研究", 《腹部外科》 * |
| 张怡，等: "新的肌肉因子——鸢尾素", 《中国生物化学与分子生物学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113267636A (en) * | 2021-06-07 | 2021-08-17 | 苏州大学附属第一医院 | Application of P2Y12 receptor and antagonist thereof in diagnosis and treatment of acute pancreatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108635571B (en) | 2021-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Reactive oxygen species differently regulate renal tubular epithelial and interstitial cell proliferation after ischemia and reperfusion injury | |
| Xia et al. | Green tea polyphenols attenuate hepatic steatosis, and reduce insulin resistance and inflammation in high-fat diet-induced rats | |
| Gonzenbach et al. | Delayed anti-nogo-a antibody application after spinal cord injury shows progressive loss of responsiveness | |
| Zeng et al. | Pathologically high intraocular pressure induces mitochondrial dysfunction through Drp1 and leads to retinal ganglion cell PANoptosis in glaucoma | |
| Xie et al. | Activated AMPK mitigates diabetes-related cognitive dysfunction by inhibiting hippocampal ferroptosis | |
| Kong et al. | Prevention of Streptozotocin‐Induced Diabetic Nephropathy by MG132: Possible Roles of Nrf2 and IκB | |
| Jin et al. | Sulodexide prevents peripheral nerve damage in streptozotocin induced diabetic rats | |
| Wei et al. | Ghrelin inhibits proinflammatory responses and prevents cognitive impairment in septic rats | |
| Li et al. | A modified bilateral carotid artery stenosis procedure to develop a chronic cerebral hypoperfusion rat model with an increased survival rate | |
| Hu et al. | Postconditioning with sevoflurane ameliorates spatial learning and memory deficit after hemorrhage shock and resuscitation in rats | |
| Wang et al. | The time course effects of electroacupuncture on promoting skeletal muscle regeneration and inhibiting excessive fibrosis after contusion in rabbits | |
| Yu et al. | De Ritis ratio as a predictor of 1-year mortality after burn surgery | |
| Xu et al. | Protective Role of Somatostatin in Sepsis‐Induced Intestinal Barrier Dysfunction through Inhibiting the Activation of NF‐κB Pathway | |
| Yang et al. | Repeated administration of adipose-derived mesenchymal stem cells added on beneficial effects of empagliflozin on protecting renal function in diabetic kidney disease rat | |
| Cesur et al. | Caudal analgesia for prostate biopsy | |
| CN108635571A (en) | Irisin（irisin）Application in preventing and treating Severe Acute Pancreatitis SAP drug | |
| Li et al. | Baicalin Ameliorates DSS‐Induced Colitis by Protecting Goblet Cells through Activating NLRP6 Inflammasomes | |
| CN103169694B (en) | Application of n-butenyl phthalide in preparing medicine for treating liver injury and improving liver function and pharmaceutical composition | |
| US20210040151A1 (en) | Micromolecule polypeptide and use thereof | |
| CN117224558A (en) | Application of RNA editing enzyme inhibitor in preparation of medicines for preventing and/or treating hepatic fibrosis | |
| CN102846666B (en) | The purposes of Chinese cobra venom after physical modification in the medicine of the acute and chronic nephropathy of preparation treatment | |
| Fan et al. | Remote ischemic preconditioning improves post resuscitation cerebral function via overexpressing neuroglobin after cardiac arrest in rats | |
| Nakashima et al. | Small-molecule protein tyrosine phosphatase inhibition as a neuroprotective treatment after spinal cord injury in adult rats | |
| Cao et al. | Magnesium hydride attenuates intestinal barrier injury during hemorrhage shock by regulating neutrophil extracellular trap formation via the ROS/MAPK/PAD4 pathway | |
| CN116271046A (en) | Use of substances specifically binding to KLK8 for the preparation of products for the prevention, treatment or diagnosis of sepsis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220225 Address after: 518066 1201, building a, phase I, Qianhai economic and Trade Center, China Merchants Group, No. 151, Zimao West Street, Nanshan street, Qianhai Shenzhen Hong Kong cooperation zone, Shenzhen, Guangdong Province Patentee after: Chonghao Technology Co.,Ltd. Address before: 710061 No. 277, Yanta West Road, Shaanxi, Xi'an Patentee before: THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XI'AN JIAOTONG University |